Paper40156757
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.
Gjølberg TT and 5 others. BioDrugs, 2025. Cited by 22 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress. Papers, record 40156757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40156757
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Fc | Major topic |
| Histocompatibility Antigens Class I | Major topic |
| Autoimmune Diseases | Major topic |
| Humans | |
| Animals | |
| Immunoglobulin G | |
| Autoantibodies |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 333902 | Norges Forskningsråd | PubMed | ||
| 332727 | Norges Forskningsråd | PubMed | ||
| 0090894 | Novo Nordisk Foundation | PubMed |
Source PubMed
References357
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33742786 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. | Clin Transl Sci | 2021 | https://conductscience.org/library/papers/33742786 | PubMed |
| 2 | 15682382 | Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. | J Pharm Sci | 2005 | https://conductscience.org/library/papers/15682382 | PubMed |
| 3 | 31354709 | The Neonatal Fc Receptor (FcRn): A Misnomer? | Front Immunol | 2019 | https://conductscience.org/library/papers/31354709 | PubMed |
| 4 | 33452006 | Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. | Ann Rheum Dis | 2021 | https://conductscience.org/library/papers/33452006 | PubMed |
| 5 | 32797372 | Satralizumab: First Approval. | Drugs | 2020 | https://conductscience.org/library/papers/32797372 | PubMed |
| 6 | 30283735 | 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. | Eur Thyroid J | 2018 | https://conductscience.org/library/papers/30283735 | PubMed |
| 7 | 8125126 | Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. | Eur J Immunol | 1994 | https://conductscience.org/library/papers/8125126 | PubMed |
| 8 | 24373505 | A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. | J Autoimmun | 2014 | https://conductscience.org/library/papers/24373505 | PubMed |
| 9 | 22110902 | Juvenile myasthenia gravis: a paediatric perspective. | Autoimmune Dis | 2011 | https://conductscience.org/library/papers/22110902 | PubMed |
| 10 | 28062799 | A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life. | Mol Cell Proteomics | 2017 | https://conductscience.org/library/papers/28062799 | PubMed |
| 11 | 16908486 | Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16908486 | PubMed |
| 12 | 12794168 | Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. | J Immunol | 2003 | https://conductscience.org/library/papers/12794168 | PubMed |
| 13 | 7969491 | Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. | Nature | 1994 | https://conductscience.org/library/papers/7969491 | PubMed |
| 14 | 20581680 | Acquired myasthenia gravis in childhood. | Curr Opin Neurol | 2010 | https://conductscience.org/library/papers/20581680 | PubMed |
| 15 | 23829325 | H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. | Transfusion | 2014 | https://conductscience.org/library/papers/23829325 | PubMed |
| 16 | 33219142 | Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. | Neurology | 2021 | https://conductscience.org/library/papers/33219142 | PubMed |
| 17 | 32795110 | Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. | MAbs | 2020 | https://conductscience.org/library/papers/32795110 | PubMed |
| 18 | 39674966 | Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis. | Immunol Res | 2024 | https://conductscience.org/library/papers/39674966 | PubMed |
| 19 | 2107806 | Dissociation of immune responses to the SS-A (Ro) 52-kd and 60-kd polypeptides in systemic lupus erythematosus and Sjögren's syndrome. | Arthritis Rheum | 1990 | https://conductscience.org/library/papers/2107806 | PubMed |
| 20 | 30130439 | Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. | MAbs | 2018 | https://conductscience.org/library/papers/30130439 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42729864 | Structure and function of therapeutic antibodies approved by the US FDA in 2025. | Antib Ther | 2026 | https://conductscience.org/library/papers/42729864 | PubMed |
| 42534577 | Novel biopharmaceutical strategies: Fc-fusion protein technology. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42534577 | PubMed |
| 42430031 | Systemic Inflammation as a Modulator of FcRn-dependent IgG Pharmacokinetics: Implications for Broadly Neutralising Antibody Efficacy in HIV Prevention. | Curr HIV/AIDS Rep | 2026 | https://conductscience.org/library/papers/42430031 | PubMed |
| 42388397 | Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions. | Ther Adv Neurol Disord | 2026 | https://conductscience.org/library/papers/42388397 | PubMed |
| 42257855 | Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases. | Inflamm Res | 2026 | https://conductscience.org/library/papers/42257855 | PubMed |
| 42162557 | Depletion and recovery of IgG following treatment with an anti-FcRn antibody and IdeS in pigtail macaques. | Clin Exp Immunol | 2026 | https://conductscience.org/library/papers/42162557 | PubMed |
| 41880580 | Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41880580 | PubMed |
| 41742631 | Systemic Manifestations of Neonatal Lupus in an Infant Born to an Asymptomatic Mother: A Case Report of Anemia and Transaminitis. | Am J Case Rep | 2026 | https://conductscience.org/library/papers/41742631 | PubMed |
| 41598737 | Anti-GQ1b Antibody Syndrome: A Clinician-Oriented Perspective on Diagnostics, Therapy, and Atypical Phenotypes-With an Illustrative 16-Case Institutional Series. | J Clin Med | 2026 | https://conductscience.org/library/papers/41598737 | PubMed |
| 41590994 | Precision Immunomodulation in Pregnancy - Lessons from Nipocalimab. | NEJM Evid | 2026 | https://conductscience.org/library/papers/41590994 | PubMed |
| 41304800 | Does a Polycistronic 2A Design Enable Functional FcRn Production for Antibody Pharmacokinetic Studies? | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41304800 | PubMed |
| 41292880 | Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques. | bioRxiv | 2025 | https://conductscience.org/library/papers/41292880 | PubMed |
| 41246121 | Advancing the Therapeutic Frontier in Thyroid Eye Disease. | touchREV Endocrinol | 2025 | https://conductscience.org/library/papers/41246121 | PubMed |
| 40843677 | FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia. | Antibodies (Basel) | 2025 | https://conductscience.org/library/papers/40843677 | PubMed |
| 40824232 | Evaluation of Immune Functions in Transfusion-Dependent Thalassemia Patients with Alloimmunization | Turk J Haematol | 2025 | https://conductscience.org/library/papers/40824232 | PubMed |
| 40821792 | The FcRn from gene to protein and function: comparison between species. | Front Immunol | 2025 | https://conductscience.org/library/papers/40821792 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| FCGRT | 2217 | PubTator's text mining | https://conductscience.org/library/genes/2217 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40156757
GET https://conductscience.org/api/papers/v1/40156757/references?page=2